SKIN & AESTHETICS / FAQ
Questions From the Literature
Direct, citation-anchored answers to what readers most often ask about GHK-Cu and the GLOW blend.
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide that acts as a collagen-synthesis signal and a copper chaperone. At picomolar-to-nanomolar concentrations it tells dermal fibroblasts to increase synthesis of collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the enzymes that break down matrix against their natural inhibitors [4][6]. In topical clinical trials, it raised procollagen synthesis in 70% of treated subjects, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison [1]. The copper ion itself enables lysyl oxidase-mediated cross-linking and a superoxide-dismutase-like antioxidant action. Most of this human evidence is topical; injectable use is unapproved and research-only.
What is GHK-Cu and how does it work?
GHK-Cu is glycyl-L-histidyl-L-lysine chelated one-to-one to a copper(II) ion. The same GHK sequence appears naturally inside the alpha-2(I) chain of type I collagen, which is the structural backbone of skin, tendon and other connective tissue [4]. That lineage explains its mechanism: liberated from collagen during remodeling or added exogenously, GHK-Cu appears to signal a repair response in the local fibroblast population. The dose-response in human fibroblast cultures has been characterized — stimulation begins between 10^-12 and 10^-11 M and peaks at around 10^-9 M, without any change in cell number [7]. Beyond single-cell signaling, a gene-expression analysis found GHK shifts expression of approximately 31.2% of human genes at a 50%-or-greater threshold, predominantly upregulating repair, antioxidant and protein quality-control programs [2].
Is GHK-Cu peptide really anti-aging?
There is real — if modest and mostly topical — human evidence for skin benefits. Clinical trial reviews document that topical GHK-Cu increased collagen production in about 70% of treated women versus 50% for vitamin C, with placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [4]. Three honest caveats belong with that: first, the dramatic "~4,000 genes" claim circulating online is an extrapolation; the verified 50%-threshold data covers roughly 2,100 genes [2]. Second, the peptide crosses intact skin poorly on its own (cLogP -2.24), which limits how much reaches the dermis without delivery aids [1]. Third, the term "anti-aging" covers a range of claims; injectable or systemic use for systemic anti-aging effects is unproven and involves an unapproved route.
What is the difference between GHK and GHK-Cu?
GHK is the bare tripeptide — glycyl-histidyl-lysine. GHK-Cu is that same tripeptide chelated (bound in a stable grip) to a copper(II) ion. The difference is not cosmetic. Copper coordination is required for most of GHK's reported biological activities — collagen synthesis stimulation, the antioxidant effect, lysyl oxidase activation — so the form used in a given study genuinely matters [4]. The two are frequently conflated in secondary sources, but in research contexts when the claim is about collagen synthesis or matrix remodeling, it is typically GHK-Cu, the copper complex, doing the work.
What is GLOW peptide?
GLOW is a research-use-only multi-peptide blend — not a single molecule. The most commonly cited formulation combines three peptides: GHK-Cu (the copper tripeptide), BPC-157 (a 15-amino-acid gastric pentadecapeptide), and TB-500 (a 7-amino-acid actin-binding fragment of thymosin beta-4) [8]. Exact ratios vary by supplier and are not standardized. The blend is positioned around skin aesthetics and tissue repair, but the combination itself has never been tested in a controlled clinical study; all its efficacy claims are extrapolated from single-constituent research. It is not FDA-approved, and two of its three components are prohibited in sport by WADA [8].
What does the GLOW peptide do?
The three GLOW constituents each target a different part of the repair process, according to the single-compound literature. GHK-Cu signals matrix remodeling — collagen and elastin synthesis [4][6]. BPC-157 is argued to support angiogenesis — new blood-vessel growth — via VEGFR2 activation, based on work in animal and human endothelial cell models [10]. TB-500 is linked to cell migration and anti-scarring effects derived from the actin-binding activity of thymosin beta-4 [8]. The combination rationale is that these three signals are complementary. However, no controlled study has tested the GLOW blend as a unit, and a 2026 Sports Medicine review naming all three components together concluded that rigorous human safety data are scarce [8].
What does GLOW peptide have in it?
A commonly cited formulation contains GHK-Cu at approximately 50 mg, BPC-157 at approximately 10 mg, and TB-500 at approximately 10 mg per research vial — though ratios and purity are supplier-specific and unverified outside formal analysis. GHK-Cu (CAS 89030-95-5, MW approximately 402.9 Da) is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine; BPC-157 (sequence GEPPPGKPADDAGLV, MW approximately 1419 Da) is a synthetic gastric pentadecapeptide; TB-500 (Ac-LKKTETQ, MW approximately 889 Da) is the acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 [8]. There is no regulatory or pharmacopoeial standard for the GLOW combination.
What peptides are in the GLOW blend?
The three peptides are GHK-Cu, BPC-157 and TB-500. GHK-Cu is the copper-tripeptide matrix-building component; its single-compound literature includes human topical trials and in vitro fibroblast dose-response data [4][7]. BPC-157 is the angiogenic and cytoprotective component; its human data consist of three small pilot studies [9]. TB-500 is the thymosin beta-4 actin-binding fragment; most of its efficacy literature uses the full-length parent protein rather than the marketed 7-mer fragment, and it is WADA-prohibited at all times [8]. Those three provenance stories are distinct, and none of their combination pharmacology has been characterized.
Is GHK-Cu WADA-prohibited?
GHK-Cu is not currently itemized by name on the WADA Prohibited List as of the 2024-2025 versions, which distinguishes it from BPC-157 and TB-500. However, WADA's catch-all S0 category can apply to non-approved pharmacological substances, so the current list should always be verified before any athletic-research context. Practically: the GLOW blend — which contains TB-500 (thymosin beta-4, explicitly WADA S2 prohibited) and BPC-157 (WADA S0 prohibited) — is prohibited for tested athletes regardless of the GHK-Cu component's individual status [8].
Is the GLOW blend safe?
No combination safety data for the GLOW blend exist — that is the core honest answer. No controlled clinical trial of GHK-Cu + BPC-157 + TB-500 together has been published. The best-characterized human data for the most data-poor GLOW component (BPC-157) comes from three small pilot studies, and a 2025 narrative review concluded BPC-157 should be treated as investigational, with caution, pending well-designed trials [9]. A 2026 Sports Medicine review addressing all three components together concluded that potential for serious harm exists and that these compounds operate largely outside regulatory oversight [8]. That framing — investigational, unknown combination profile, regulatory gray area — is the accurate summary of what is known.
Does GHK-Cu work for hair loss?
There is one controlled human trial supporting a GHK-containing topical for hair loss. In a 6-month RCT of 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus only 9.6 for placebo, with no adverse events in any group [3]. The caveat is important: this tested a combination product, not pure GHK-Cu, so it is not possible to attribute the effect exclusively to the GHK sequence. The mechanistic case — GHK-Cu stimulates hair follicle dermal papilla cells and promotes anagen signaling — comes from in vitro and review literature [4][6]. Injectable use for hair loss is unapproved and has no human trial data.